Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm<sup>3</sup>
<p>Abstract</p> <p>Background</p> <p>Antiretroviral therapy (ART) with a generic fixed-dose combination (FDC) of stavudine (d4T)/lamivudine (3TC)/nevirapine (NVP) is widely used in developing countries. The clinical data of this FDC among very advanced HIV-infected pati...
Main Authors: | Likanonsakul Sirirat, Chimsuntorn Sukanya, Manosuthi Weerawat, Sungkanuparph Somnuek |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2007-03-01
|
Series: | AIDS Research and Therapy |
Online Access: | http://www.aidsrestherapy.com/content/4/1/6 |
Similar Items
-
Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Prior Co-administration of Rifampicin: A 144-week Prospective Study
by: Prasithisirikul Wisit, et al.
Published: (2008-10-01) -
Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
by: Suntisuklappon Busakorn, et al.
Published: (2010-10-01) -
The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience
by: Nwauche CA, et al.
Published: (2009-09-01) -
Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole
by: Phoorisri Thanongsri, et al.
Published: (2007-03-01) -
Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study
by: Chaovavanich Achara, et al.
Published: (2005-08-01)